



Prof. Esteban CVITKOVIC, M.D, PhD, HC

Prof. CVITKOVIC, born in Buenos Aires, completed his medical degree in Argentina in 1969, at age of 19 (world's youngest physician), and where he then began his oncology training.

With over almost 40 years of international specialized practice and academic experience: Argentina (Instituto Roffo, Hospital Militar), Italy (Istituto Tumori and Istituto Mario Negri, Milano), US (Columbia Presbyterian, Memorial Sloan Kettering, New York) and France (Institut Gustave Roussy, Villejuif, Hospital Beaujon and Hospital Saint Louis, Paris), Prof. Cvitkovic has authored over 200 peer-reviewed articles and solicited reviews of 600 abstracts, while training dozens of oncology specialists, many of them current leaders in academic and industry R&D.

A medical oncologist focused on solid tumours, early/intermediate drug development and therapeutic optimisation, Prof. Cvitkovic has been instrumental in defining the clinical utility and enabling the registrations of many oncology drugs including cisplatin, vindesine, bleomycin, navelbine, and amifostine. Oxaliplatin, irinotecan, docetaxel and ET-743 are amongst his latest milestone contributions. On the disease front he led concomitant therapeutic advances in germ cell tumours, squamous head and neck cancer, EBV-related nasopharyngeal carcinoma, colorectal carcinoma, pancreatic cancer and soft tissue sarcomas.

While keeping throughout his career a part-time medical and academic practice, and based in Paris, France over the last 25 years, Prof. Cvitkovic established an international oncology-specialized full service clinical CRO, Cvitkovic & Associés Consultants SA, sold in 2006 to AAIPharma, where he consulted broadly in early stage clinical development of a wide range of oncology treatments. Prof. Cvitkovic heads the Scientific Board of FNAB (Foundation Nelia & Amadeo Barletta), a non-profit Swiss/French entity focused exclusively on the support of international translational initiatives leading to individualized cancer treatment.

He was founder and CSO of OncoEthix, a Lausanne based Biotech Company founded in 2008, focused on first-in-man/early development of oncology therapies, sold in 2014 to Merck. He is CEO of Oncology Therapeutic Development (OTD), a small multiservice CRO also focused in early development in Oncology. He holds an operational consulting role with Medicxi (London), for oncology related.